Safety, tolerability and pharmacokinetics (PK) of single and repeat nebulised doses of a novel phosphoinositide 3-kinase Δ inhibitor (PI3KΔ), GSK2269557, administered to healthy male subjects in a phase I study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
A multicompartmemt lung model predicts pulmonary pharmacokinetics of inhaled liposomal treprostinil (L606) in healthy volunteer Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Source: Eur Respir J 2006; 28: 1042-1050 Year: 2006
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Esterification prolongs retention of budesonide but not ciclesonide - active principle in rat trachea Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis Source: Eur Respir J 2002; 19: 294-302 Year: 2002
Pharmacokinetics of selective PI3Kδ inhibitors after intratracheal instillation in mice Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Greater esterification and retention of budesonide in the airways and lung as compared to ciclesonide after repeated intratracheal administration in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 345s Year: 2004
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009) Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Penetration and pharmacokinetics of peramivir in upper and lower airway epithelia and plasma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014